Current Oncology Reports

, Volume 4, Issue 2, pp 175–184 | Cite as

Human papillomavirus in cervical cancer

  • F. Xavier Bosch
  • Silvia de Sanjosé
Article

Abstract

Epidemiologic studies supported by molecular technology have provided sufficient evidence of the causal role of some human papillomavirus (HPV) infections in the development of cervical cancer. The finding is consistent universally, and HPV has been proposed as the first identified necessary cause of cervical cancer. Such recognition translates into the concept that cervical cancer does not develop without persistent presence of HPV DNA. In the developed parts of the world, cytologic screening programs could benefit from the addition of HPV testing to their protocols. Controlled studies and one randomized trial have shown that HPV testing is helpful in solving the ambiguous cases generated by cytology reading. In populations where cytology programs are not functional or efficient, HPV testing is being evaluated as an alternative means of primary screening. Prevention of exposure to high-risk HPV types, either by prophylactic vaccination or by combined prophylactic and therapeutic immunologic intervention, may prove to be the most efficient and logistically feasible option for the prevention of cervical cancer in developing populations.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Bosch FX, Manos MM, Muñoz N, et al., for the International Biological Study on Cervical Cancer (IBSCC) Study Group: Prevalence of human papillomavirus cervical cancer: a worldwide perspective. J Natl Cancer Inst 1995, 87:796–802.PubMedCrossRefGoogle Scholar
  2. 2.
    Walboomers JM, Jacobs MV, Manos MM, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12–9. Along with Bosch et al. [1], this paper reports on an exhaustive investigation of the presence of viral DNA in over 1000 cervical cancer cases from 22 countries. The final reported prevalence of 99.7% generated the claim that HPV is in fact a necessary cause of cervical cancer.PubMedCrossRefGoogle Scholar
  3. 3.
    Bosch FX, Rohan T, Schneider A, et al.: Papillomavirus research update: highlights of the Barcelona HPV 2000 International Papillomavirus Conference. J Clin Pathol 2001, 54:163–175.PubMedCrossRefGoogle Scholar
  4. 4.
    Castellsagué X, Menéndez C, Loscertales M-P, et al.: Human papillomavirus genotypes in rural Mozambique. Lancet 2001, 358:1429.PubMedCrossRefGoogle Scholar
  5. 5.
    Xi LF, Koutsky LA, Galloway DA, et al.: Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. J Natl Cancer Inst 1997, 89:796–802.PubMedCrossRefGoogle Scholar
  6. 6.
    Hildesheim A, Schiffman M, Bromley C, et al.: Human papillomavirus type 16 variants and risk of cervical cancer. J Natl Cancer Inst 2001, 93:315–318.PubMedCrossRefGoogle Scholar
  7. 7.
    Josefsson AM, Agnetha M, Magnusson PKE, et al.: Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. Lancet 2000, 355:2189–2193. This paper represents an evaluation of HPV viral load as an additional test to predict progression in screening specimens at stages in which cytology is uninformative. It is one of the first studies to include quantitative PCR to generate estimates of the viral load.PubMedCrossRefGoogle Scholar
  8. 8.
    Ylitalo N, Josefsson A, Melbye M, et al.: A prospective study showing long-term infection with human papillomavirus 16 before the development of cervical carcinoma in situ. Cancer Res 2000, 60:6027–6032.PubMedGoogle Scholar
  9. 9.
    Thomas DB, Ray RM, Koetsawang A, et al.: Human papillomaviruses and cervical cancer in Bangkok. I. Risk factors for invasive cervical carcinomas with human papillomavirus types 16 and 18 DNA. Am J Epidemiol 2001, 153:723–731. This is the most recent report on a large case-control study on HPV and cervical cancer. It confirms the key findings of the previous studies by Bosch et al. [3] and Herrero et al. [12] on the extremely high relative risk estimates for the presence of HPV DNA as a determinant of invasive cervical cancer or preinvasive cervical neoplasm.PubMedCrossRefGoogle Scholar
  10. 10.
    Franco EL, Villa LL, Sobrinho JP, et al.: Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer. J Infect Dis 1999, 180:1415–1423.PubMedCrossRefGoogle Scholar
  11. 11.
    Ho GYF, Biermal R, Beardsley L, et al.: RD: Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338:423–428.PubMedCrossRefGoogle Scholar
  12. 12.
    Herrero R, Hildesheim A, Bratti C, et al.: Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000, 92:464–474.PubMedCrossRefGoogle Scholar
  13. 13.
    Lazcano-Ponce E, Herrero R, Muñoz N, et al.: Epidemiology of HPV infection among mexican women with normal cervical cytology. Int J Cancer 2001, 91:1–9.CrossRefGoogle Scholar
  14. 14.
    Jacobs MV, Walboomers JMM, Snijders PJF, et al.: Distribution of 37 mucosotropic HPV types in women with cytologically normal cervical smears: the age-related patterns for high-risk and low-risk types. Int J Cancer 2000, 87:221–227.PubMedCrossRefGoogle Scholar
  15. 15.
    Parkin DM, Whelan SL, Ferlay J, et al.: Cancer Incidence in Five Continents, vol 7. Lyon: IARC Scientific Publications; 1997.Google Scholar
  16. 16.
    Nobbenhuis MAE, Walboomers JMM, Helmerhorst TJM, et al.: Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 1999, 354:20–25.PubMedCrossRefGoogle Scholar
  17. 17.
    Rozendaal L, Walboomers JM, van der Linden JC, et al.: PCRbased high-risk HPV test in cervical cancer screening gives objective risk assessment of women with cytomorphologically normal cervical smears. Int J Cancer 1996, 68:766–769.PubMedCrossRefGoogle Scholar
  18. 18.
    Rozendaal L, Westerga J, van der Linden JC, et al.: PCR based high risk HPV testing is superior to neural network based screening for predicting incident CIN III in women with normal cytology and borderline changes. J Clin Pathol 2000, 53:606–611.PubMedCrossRefGoogle Scholar
  19. 19.
    Manos MM, Kinney WK, Hurley LB, et al.: Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results. JAMA 1999, 281:1605–1610.PubMedCrossRefGoogle Scholar
  20. 20.
    Zielinski GD, Snijders PJF, Rozendaal L, et al.: HPV presence precedes abnormal cytology in women developing cervical cancer and signals false negative smears. Br J Cancer 2001, 85:398–404.PubMedCrossRefGoogle Scholar
  21. 21.
    Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, et al.: Cytological regression and clearance of high-risk human papillomavirus in women with abnormal cervical smear. Lancet 2001, 358:1782–1783.PubMedCrossRefGoogle Scholar
  22. 22.
    Nobbenhuis MA, Meijer CJ, van den Brule AJ, et al.: Addition of high-risk HPV testing improves the current guidelines on follow-up after treatment for cervical intraepithelial neoplasia. Br J Cancer 2001, 84:796–801. Description of the ability of the HPV tests after conization to predict CiN2 or 3 at 24 months following treatment. The sensitivity at 6 months of an HPV test was 90%, compared with cytology at 62%. The negative predictive value of an HPV result was 99%. The study was based on 184 women with a 24-month follow-up and 29 CiN2 or 3 events.PubMedCrossRefGoogle Scholar
  23. 23.
    Wallin K-L, Wiklund F, Angstr;om T, et al.: Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer. N Engl J Med 1999, 341:1633–1638.PubMedCrossRefGoogle Scholar
  24. 24.
    Dillner J, Lehtinen M, Bjorge T, et al.: Prospective seroepidemiologic study of human papillomavirus infection as a risk factor for invasive cervical cancer. J Natl Cancer Inst 1997, 89:1293–1299.PubMedCrossRefGoogle Scholar
  25. 25.
    zurHausen H: Papillomavirus causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 2000, 92:690–698.CrossRefGoogle Scholar
  26. 26.
    Shah KV, Howley PM: Papillomaviruses. In Field’s Virology. Edited by Knipe DM, Howley PM. Philadelphia: Lippincott-Raven; 1996:2077–2109.Google Scholar
  27. 27.
    Lazo PA: The molecular genetics of cervical carcinoma. Br J Cancer 1999, 80:2008–2018.PubMedCrossRefGoogle Scholar
  28. 28.
    Thomas KK, Hughes JP, Kuypers JM, et al.: Concurrent and sequential acquisition of different genital human papillomavirus types. J Infect Dis 2000, 182:1097–102.PubMedCrossRefGoogle Scholar
  29. 29.
    Schiller JT, Lowy DR: Papillomavirus-like particle vaccines. J Natl Cancer Inst Monogr 2000, 28:50–54.Google Scholar
  30. 30.
    Nanda K, McCrory DC, Myers ER, et al.: Accuracy of the Papanicolau test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000, 132:810–819. This is an updated meta-analysis of the relative value of cytology as a screening test. The authors report sensitivity of close to 50% and specificity of 98%.PubMedGoogle Scholar
  31. 31.
    Kleter B, van Doorn LJ, ter Schegget J, et al.: Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998, 153:1731–1739.PubMedGoogle Scholar
  32. 32.
    Gravitt PE, Peyton CL, Alessi TQ, et al.: Improved amplification of genital human papillomaviruses. J Clin Microbiol 2000, 38:357–361.PubMedGoogle Scholar
  33. 33.
    Hutchinson ML, Zahniser DJ, Sherman et al.: Utility of liquidbased cytology for cervical carcinoma screening: results of a population-based study conducted in a region of Costa Rica with a high incidence of cervical carcinoma. Cancer 1999, 87:48–55.PubMedCrossRefGoogle Scholar
  34. 34.
    Clavel C, Measure M, Levert M, et al.: Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions. Diagn Mol Pathol 2000, 9:145–150.PubMedCrossRefGoogle Scholar
  35. 35.
    Solomon D, Schiffman M, Tarone R: Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial. J Natl Cancer Inst 2001, 93:293–299. With the report from the ALTS group [47], this paper represents the first large randomized trial to evaluate clinical management of cytology results diagnosed as ASCUS or LSIL. The authors confirm the value of HPV testing over repeated cytology in clarifying the prognosis of an ambiguous expert cytology, classified according to the Bethesda system.PubMedCrossRefGoogle Scholar
  36. 36.
    Kuhn L, Denny L, Pollack A, et al.: Human papillomavirus DNA testing for cervical cancer screening in low-resource settings. J Natl Cancer Inst 2000, 92:818–825.PubMedCrossRefGoogle Scholar
  37. 37.
    Schiffman MH, Herrero R, Hildesheim A, et al.: HPV DNA testing in cervical cancer screening. JAMA 2000, 283:87–93.PubMedCrossRefGoogle Scholar
  38. 38.
    Belinson J, Qiao Y, Pretorius R, et al.: Prevalence of cervical cancer and feasibility of screening in rural China: a pilot study for the Shanxi Province Cervical Cancer Screening Study. Int J Gynecol Cancer 1999, 9:411–417.PubMedCrossRefGoogle Scholar
  39. 39.
    Womack SD, Chirenje ZM, Gaffikin L, et al.: HPV-based cervical cancer screening in a population at high risk for HIV infection. Int J Cancer 2000, 85:206–210.PubMedGoogle Scholar
  40. 40.
    Ratnam S, Franco EL, Ferenczy A: Human papillomavirus testing for primary screening of cervical cancer precursors. Cancer Epidemiol Biomarkers Prevent 2000, 9:945–951.Google Scholar
  41. 41.
    Schneider A, Hoyer H, Lotz B, et al.: Screening for high-grade cervical intra-epithelial neoplasia and cancer by testing for high-risk HPV, routine cytology or colposcopy. Int J Cancer 2000, 89:529–534.PubMedCrossRefGoogle Scholar
  42. 42.
    Blumenthal PD, Gaffikin L, Chirenje ZM, et al.: Adjunctive testing for cervical cancer in low resource settings with visual inspection, HPV, and the Pap smear. Int J Gynecol Obstet 2001, 72:47–53.CrossRefGoogle Scholar
  43. 43.
    Wright TC Jr, Denny L, Kuhn L, et al.: HPV DNA testing of selfcollected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 2000, 283:81–86.PubMedCrossRefGoogle Scholar
  44. 44.
    Cuzick J, Beverley E, Ho L, Terry G, Sapper H, Mielzynska I, Lorinzc A, Chan W-K, Krausz T, Soutter P: HPV testing in primary screening of older women. Br J Cancer 1999, 81(3):554–58.PubMedCrossRefGoogle Scholar
  45. 45.
    Goldie SJ, Kuhn L, Denny L, et al.: Policy Analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA 2001, 285:3107–3115.PubMedCrossRefGoogle Scholar
  46. 46.
    Solomon D: The 1988 Bethesda system for reporting cervical/ vaginal cytologic diagnoses. Developed and approved at the National Cancer Institute Workshop, Bethesda, Maryland, USA, December, 12–13, 1988. J Clin Cytol Cytopathol 1989, 33:567–574.Google Scholar
  47. 47.
    The Atypical Squamous Cell of Undetermined Significance/ Low-grade squamous Intraepithelial Lesions Triage Study (ALTS) Group: Human papillomavirus testing for triage of women with cytologic evidence of low-grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst 2000, 92:397–402. With Solomon et al. [35], this report finds an HPV prevalence in LSIL of 83%, suggesting that, under these diagnostic conditions, HPV testing would not be of value as a triage for coloscopy criteria.CrossRefGoogle Scholar
  48. 48.
    Sellors JW, Mahony JB, Kaczorowski J, et al., for the Survey of HPV in Ontario Women (SHOW): Group prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. CMAJ 2000, 163:503–508.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • F. Xavier Bosch
    • 1
  • Silvia de Sanjosé
    • 1
  1. 1.Servei d’Epidemiologia i Registre del Càncer, Institut Català d’OncologiaL’Hospitalet de LlobregatSpain

Personalised recommendations